Home About Us Contact Us

 

Table of Content - Volume 13 Issue 1 - Janauary 2020


 


Baseline characteristics and immunological response to antiretroviral therapy in HIV-2 patients

 

Kashmira Rajendra Hajare1, Rahul Kadu2*, Priya Patil3

 

1,2 Assistant Professor, 3Associate Professor, Department of Medicine, GGMC and JJ Hospital, Mumbai, Maharashtra, INDIA.

Email: kash.hajare@rediffmail.com,rahulkadu65@gmail.com,priya0312@yahoo.com

 

REFERENCES

  1. Andersson S, Norrgren H, DaSilva Z, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: Significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infections. Arch Intern Med 2000;160: 3286-93.
  2. Marlink R, Kani P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-90.
  3. De Silva TI, Cotten M, Rowland-Jones SL. HIV-2: The forgotten AIDS virus. Trends Microbiol 2008;16:588-95.
  4. van der Loeff MF, Larke N, Kaye S, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010;7: 46.
  5. Haynes BF, Pantaleo G, Fauci AS. Towards an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271:324-8.
  6. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol 1996; 50: 825-54.
  7. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS. 2008; 22(4):457-68.
  8. Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis. 2008; 8:21.
  9. Harries K, Zachariah R, Manzi M, Firmenich P, Mathela R, Drabo J, et al. Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso. Trans R Soc Trop Med Hyg. 2010;104(2): 154-61.
  10. Chiara M, Rony Z, Homa M, Bhanumati V, Ladomirska J, Manzi M, et al. Characteristics, immunological response and treatment outcomes of HIV-2 compared with HIV-1 and dual infections (HIV 1/2) in Mumbai. Indian J Med Res. 2010 Dec;132: 683-9.
  11. Ilovi CS. Correlation of WHO clinical staging with CD4 counts in adult HIV/AIDS patients at KNH.; 2011.
  12. van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003, 17(Suppl 3):S55–S61.
  13. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al. HIV2 Cohort Study Group: CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006, 20(3):459-62.